BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD
5.82
-0.10 (-1.69%)
At close: Feb 20, 2024, 4:00 PM
5.75
-0.07 (-1.20%)
After-hours: Feb 20, 2024, 7:13 PM EST
-1.69%
Market Cap 1.19B
Revenue (ttm) 317.56M
Net Income (ttm) -236.35M
Shares Out 204.81M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,424,091
Open 5.75
Previous Close 5.92
Day's Range 5.71 - 5.95
52-Week Range 4.83 - 9.85
Beta 1.91
Analysts Strong Buy
Price Target 13.63 (+134.19%)
Earnings Date Feb 26, 2024

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 3, 1994
Employees 531
Stock Exchange NASDAQ
Ticker Symbol BCRX
Full Company Profile

Financial Performance

In 2022, BCRX's revenue was $270.83 million, an increase of 72.31% compared to the previous year's $157.17 million. Losses were -$247.12 million, 34.3% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price forecast is $13.63, which is an increase of 134.19% from the latest price.

Price Target
$13.63
(134.19% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioCryst Launches ORLADEYO® (berotralstat) in Italy

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), ha...

1 day ago - GlobeNewsWire

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on ...

8 days ago - GlobeNewsWire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of re...

15 days ago - GlobeNewsWire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n...

18 days ago - GlobeNewsWire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales...

6 weeks ago - GlobeNewsWire

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Co...

6 weeks ago - GlobeNewsWire

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment with ORLADEYO – – Results published in JACI: In Prac...

2 months ago - GlobeNewsWire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANM...

2 months ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Co...

3 months ago - GlobeNewsWire

BioCryst Launches ORLADEYO® (berotralstat) in Spain

RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted m...

3 months ago - GlobeNewsWire

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

– Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across 12-month period – – Additional analysis from APe...

3 months ago - GlobeNewsWire

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced updates from its drug discovery process and additional therapies from its...

3 months ago - GlobeNewsWire

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –

3 months ago - GlobeNewsWire

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO reven...

3 months ago - GlobeNewsWire

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® ...

4 months ago - GlobeNewsWire

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial e...

4 months ago - GlobeNewsWire

BioCryst to Host R&D Day on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November ...

4 months ago - GlobeNewsWire

BioCryst to Report Third Quarter 2023 Financial Results on November 2

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on ...

4 months ago - GlobeNewsWire

INESSS Recommends Public Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Institut national d'excellence en santé et services sociaux (INE...

5 months ago - GlobeNewsWire

Harley, Spotify, and 8 Other Dead Money Stocks That Are Poised to Come Alive

Barron's looked at stocks in the Russell 3000 that have done little for the past five years and identified 10 stocks where improving analyst sentiment could signal better days ahead.

Other symbols: SPOTBIIBBKHOGKWRLAZSMG
6 months ago - Barrons

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

— Q2 2023 ORLADEYO net revenue of $81.0 million (+24 percent y-o-y)— — On-track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue— — Q2 2023 GAAP EPS...

7 months ago - GlobeNewsWire

BioCryst to Report Second Quarter 2023 Financial Results on August 3

RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on ...

7 months ago - GlobeNewsWire

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals t...

7 months ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference on We...

9 months ago - GlobeNewsWire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-dail...

9 months ago - GlobeNewsWire